NEPHROPLUS2026-04-012026-06-30NEPHROPLUS2026-04-012026-06-30in-capmkt:OtherExpenses1MemberNEPHROPLUS2026-04-012026-06-30in-capmkt:OtherExpenses2MemberNEPHROPLUS2026-04-012026-06-30in-capmkt:OtherExpenses3MemberNEPHROPLUS2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1NEPHROPLUS2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2NEPHROPLUS2026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares544647NEPHROPLUSNOTLISTEDINE428V01029Nephrocare Health Services LimitedMain BoardEquity2026-04-012027-03-312026-08-112026-07-24INRMillionsQuarterlyFirst quarterSingle segmentHealthcare services2026-08-1115:45:002026-08-1117:10:00Not applicable2026-04-012026-06-30UnauditedConsolidated28175400007459000028921300006244100000047825000022060000245400000107605000024461700004459600000445960000120890000-30330000905600000355400000000-35660000319740000107800003305200003197400000330520000020068000023.193.11003.193.11 <br /> <br /> 1. The above consolidated financial results of Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) ("the Company") and its <br /> subsidiaries (the Company and its subsidiaries together referred to as "the Group") and its joint venture for the quarter ended 30 June 2026, have been prepared in <br /> accordance with the Indian Accounting Standard (referred to as 'Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian <br /> Accounting Standards) Rules, 2015, as amended from time to time and in terms of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and <br /> Disclosure Requirements) Regulations, 2015. <br /> <br /> 2. These consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 <br /> August 2026. The Statutory auditors of the Company have conducted a 'Limited Review' of the consolidated financial results and have issued an unmodified review <br /> conclusion thereon. <br /> <br /> 3. The consolidated figures for the quarter ended 31 March 2026 are the balancing figures between audited consolidated figures for the year ended 31 March 2026 <br /> and the published unaudited year to date figures for the nine months ended 31 December 2025. <br /> <br /> <br /> 4. The Company was listed on the stock exchanges on 17 December 2025. Accordingly, the consolidated financial results for the corresponding quarter ended 30 <br /> June 2025 were not required to be submitted to the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, <br /> 2015 and were consequently not subjected to audit or limited review by the statutory auditors. The comparative figures for the quarter ended 30 June 2025 as <br /> included in these consolidated financial results, have been approved by the Board of Directors of the Company at its meeting held on 11 August 2026. <br /> <br /> 5. The Statement of unaudited consolidated financial results include the results of the following entities: <br /> <br /> a) Parent: <br /> 1) Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) <br /> <br /> b) Subsidiaries (including step-down subsidiaries): <br /> 1) Nephrocare Health Services Central Asia FE LLC <br /> 2) Nephrocare Health Services Nepal Private Limited <br /> 3) Nehrocare Health Services International Pte Ltd <br /> 4) Nephro Plus Kidney Services Company <br /> 5) Nephrocare Health Care Services, Philippines Inc. <br /> 6) Anram Medical Group Inc. <br /> 7) Cadiz Dialysis Hub Inc. <br /> 8) Dialysis Asia and Patient Care Center Inc. <br /> 9) People’s Center For Hemodialysis Care Inc. <br /> 10) Curis Hemodialysis Clinic Inc. <br /> 11) Mega Health Dialysis Center Inc. <br /> 12) Universe Dialysis and Kidney Care Centre Inc. <br /> 13) St. Margareth Dialysis and Biocare Centre Inc. <br /> 14) Medical Experts Group and Associates Inc. <br /> 15) Curis Cavite Renal Corporation <br /> 16) Renal Therapy Solutions, Inc. <br /> 17) Rizal Dialysis and Wellness Centre OPC <br /> 18) Bioregen Hemo Center Inc. <br /> 19) Carmona Dialysis System Inc. <br /> 20) Infini Care Health Systems Inc. <br /> 21) Kolff Dialysis Inc. <br /> 22) AIZ Hemodialysis Centre Inc. <br /> 23) Nephro Alliance Ventures Inc. <br /> 24) Nephroplus Health Services Kazakhstan Limited Liability Partnership (LLP) ( w.e.f. 26 May 2026) <br /> <br /> c) Joint Venture <br /> 1) Nephrocare Health Services Saudi Arabia Company <br /> <br /> <br /> 6. The Group's Chief Operating Decision Maker ("CODM"), being the Chairman and Managing Director, reviews the financial performance and allocates resources at <br /> the Group level. The Group is principally engaged in providing dialysis services and sale of related healthcare products. Accordingly, the Group has identified a single <br /> reportable segment in accordance with Ind AS 108, Operating Segments. Geographical information is disclosed below based on the location of operations as required <br /> under Ind AS 108. <br /> <br /> Geographical information <br /> <br /> Particulars Quarter ended Year ended <br /> 30 June 2026 31 March 2026 30 June 2025 31 March 2026 <br /> Revenue from operations <br /> India 1,553.79 1,491.96 1,392.25 5,813.21 <br /> Philippines 906.29 846.75 669.37 3,112.28 <br /> Uzbekistan 321.34 287.02 216.21 1,004.22 <br /> Others 36.12 30.42 - 58.74 <br /> Total 2,817.54 2,656.15 2,277.83 9,988.45 <br /> <br /> <br /> "7. During the year ended 31 March 2026, the Company has completed an initial public offering (IPO) of 18,943,020 equity shares with a face value of INR 2 each at an issue price of INR 460 per share, comprising fresh issue of 7,689,918 shares and an offer for sale of 11,253,102 shares. The Company’s equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 17 December 2025. <br /> <br /> The utilisation of net IPO proceeds is summarised below:" <br /> <br /> <br /> <br /> Objectives Amount to be utilised as per prospectus Utilisation up to 30 June 2026 Unutilised as on 30 June 2026 <br /> Capital expenditure for opening new dialysis clinics in India 1,291.06 127.68 1,163.38 <br /> Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed 1,359.99 1,359.99 - <br /> General corporate purposes 600.48 587.16 13.32 <br /> Total 3,251.53 2,074.83 1,176.70 <br /> <br /> 8. During the quarter ended 30 June 2026, the Group entered into seven asset transfer arrangements for an aggregate consideration of INR 709.30 million. The initial accounting for these business combinations is provisional as the identification and measurement of the assets acquired are yet to be completed. Accordingly, the purchase consideration has been allocated on a provisional basis to tangible assets, intangible assets and goodwill based on management's current assessment. The Group will finalise the initial accounting within the measurement period of up to twelve months from the respective acquisition dates in accordance with Ind AS 103, Business Combinations. <br /> <br /> <br /> 9. On 26 May 2026, the Group incorporated NephroPlus Health Services Kazakhstan Limited Liability Partnership, a wholly owned subsidiary in the Republic of Kazakhstan, to expand its dialysis and related healthcare services operations in Central Asia. <br /> <br /> <br /> 10. During the quarter ended 30 June 2026, the Company received share application money amounting to INR 11.28 million pursuant to the exercise of employee stock options under its ESOP Scheme. Subsequently, on 14 July 2026, the Company allotted 144,320 equity shares against such exercises. <br /> <br /> <br /> 11. The consolidated financial results for quarter ended 30 June 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: nseindia.com) and on the Company's website (URL: https://nephroplus.com/investors). Healthcare professional fees306140000Hospital fees215870000Other expenses554040000Remeasurement gains on defined benefit plans160000Income tax relating to above items-400001200000Exchange differences on translating financial statements of foreign operations1066000010660000010780000